Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
China Pharma Holdings Inc (CPHI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: CPHI (1-star) is a SELL. SELL since 5 days. Simulated Profits (-4.95%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -83.56% | Avg. Invested days 20 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.96M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) - | Beta 0.75 | 52 Weeks Range 1.20 - 3.35 | Updated Date 06/29/2025 |
52 Weeks Range 1.20 - 3.35 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -106.3% | Operating Margin (TTM) -66.76% |
Management Effectiveness
Return on Assets (TTM) -18.22% | Return on Equity (TTM) -59.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9050107 | Price to Sales(TTM) 1.39 |
Enterprise Value 9050107 | Price to Sales(TTM) 1.39 | ||
Enterprise Value to Revenue 2.11 | Enterprise Value to EBITDA -225.89 | Shares Outstanding 3262000 | Shares Floating 2640623 |
Shares Outstanding 3262000 | Shares Floating 2640623 | ||
Percent Insiders 30.26 | Percent Institutions 1.04 |
Upturn AI SWOT
China Pharma Holdings Inc
Company Overview
History and Background
China Pharma Holdings, Inc. was founded in 2003 and is headquartered in China. It focuses on developing, manufacturing, and marketing pharmaceutical products in China.
Core Business Areas
- Pharmaceutical Products: Development, manufacturing, and commercialization of prescription and over-the-counter (OTC) pharmaceutical products.
- Traditional Chinese Medicine (TCM): Manufacturing and distribution of TCM products.
Leadership and Structure
Leadership information can be found via public filings and news releases, including names of the CEO, CFO, and board members. The organizational structure is typical of a pharmaceutical company with departments for R&D, manufacturing, sales, marketing, and administration.
Top Products and Market Share
Key Offerings
- Jinhai Qingre Xiaoyan: A prescription drug for treating upper respiratory tract infections. Market share data is difficult to acquire precisely, and likely small. Competitors are other pharmaceutical companies with similar products in the Chinese market.
- Xinkang: An OTC drug for treating cough and cold symptoms. Market share data is difficult to acquire precisely, and likely small. Competitors are other pharmaceutical companies with similar products in the Chinese market.
Market Dynamics
Industry Overview
The pharmaceutical industry in China is growing, driven by an aging population, increasing healthcare spending, and government initiatives to improve access to healthcare. The industry is also facing increasing regulatory scrutiny and competition.
Positioning
China Pharma Holdings, Inc. is a small player in a large and competitive market. Competitive advantages are not readily apparent from public information.
Total Addressable Market (TAM)
The TAM for pharmaceuticals in China is estimated to be hundreds of billions of dollars. China Pharma Holdings, Inc. has a very small market share.
Upturn SWOT Analysis
Strengths
- Established presence in China
- Diverse product portfolio
- Manufacturing capabilities
Weaknesses
- Small market share
- Limited financial resources
- Dependence on the Chinese market
Opportunities
- Growing demand for pharmaceuticals in China
- Government support for the pharmaceutical industry
- Expansion into new markets
Threats
- Increasing competition
- Regulatory changes
- Price pressures
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- NVS
- MRK
- ROG
Competitive Landscape
China Pharma Holdings, Inc. faces intense competition from larger, more established pharmaceutical companies with greater resources and wider distribution networks.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has likely been modest, given the company's small size and competitive market.
Future Projections: Future growth projections are uncertain and depend on the company's ability to innovate, expand its market share, and manage its costs.
Recent Initiatives: Recent initiatives would be detailed in press releases and SEC filings.
Summary
China Pharma Holdings, Inc. is a small pharmaceutical company operating in the highly competitive Chinese market. It faces significant challenges in growing its business and achieving profitability. Its strengths include its established presence in China and its diverse product portfolio; however, weaknesses are its small size and limited financial resources. It is unlikely to grow at a meaningful rate.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Press releases
- Market research reports (available through subscriptions, not specifically cited)
- OTCBB:CPHI data.
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise. Due to limited data, this is a preliminary analysis.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About China Pharma Holdings Inc
Exchange NYSE MKT | Headquaters - | ||
IPO Launch date 2002-04-17 | President, CEO, Chairman & Interim CFO Ms. Zhilin Li | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 224 | |
Full time employees 224 | |||
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets. It offers Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.